Sjögren’s Syndrome Market, Size, Share, Opportunities and Forecast, 2020-2027

SKU: DPH92 | Last Updated On: Oct 08 2020 | No. of Pages: 183 | Available Formats

> Global Sjögren’s Syndrome Market Expected to reach a high CAGR of 3.3% By 2027: DataM Intelligence

Global Sjögren’s Syndrome Market is segmented By Drug Class (Cholinergic Agonists, Off-Label Drugs), By Type (Primary Sjogren’s Syndrome, Secondary Sjogren’s Syndrome), By Distribution Channel (Hospitals, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027


Market Overview

  • GlobalSjögren’s Syndrome Market is expected to grow at a CAGR of 3.3% during the forecasting period (2020-2027)
  • Sjögren’s syndrome (SS) is a chronic, autoimmune, systemic, inflammatory disorder of unknown cause.
  • It is characterized by dryness of the mouth, eyes, and other mucous membranes due to lymphocytic infiltration of exocrine glands and secondary gland dysfunction.
  • There is currently no cure for Sjögren’s syndrome, but there are treatments that can help relieve the symptoms.

Market Growth:

  • Global Sjögren’s syndrome market will reach USD 2 billion by 2024, driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021.
  • Other factors driving the market include the growing patient population of diseases that can cause SS such as lupus and rheumatoid arthritis.
  • Increasing awareness and hence the demand for advanced treatment.
  • However, the lack of a cure for Sjögren’s syndrome will impact market growth.
  • Many of the currently available treatments for SS either only relieve the symptoms or are considered ineffective in many patients.

Market Segmentation:

  • Global Sjögren’s syndrome market report segments the market by type, by drug class, by distribution channel, and by region.
  • Based on the type, the market is segmented into primary Sjogren’s syndrome and secondary.
  • Secondary Sjogren’s syndrome segment dominates the market.
  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
  • North America is the largest market for Sjögren’s syndrome owing to the rising prevalence of autoimmune diseases and advanced autoimmune diagnostic testing and screening.

Market Scope of the Report:

  • The report also profiles companies in the Sjögren’s syndrome market – Novartis AG, Allergan Inc., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Argentis Pharmaceuticals, LLC., Auven Therapeutics, Bridge Pharma Inc. and Cellzome GmbH.

By Drug Class

  • Cholinergic Agonists
  • Off-Label Drugs

By Type

  • Primary Sjogren’s Syndrome
  • Secondary Sjogren’s Syndrome

By Distribution Channel

  • Hospitals
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

  • North America (The USA, Canada, Mexico)

  • South America (Brazil, Argentina, Rest of South America)

  • Rest of the World

 Why purchase the report?

  • Visualize the composition of Sjögren’s syndrome market across each indication, regarding type and treatment options, highlighting the vital commercial assets and players.
  • Identify commercial opportunities in Sjögren’s syndrome market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for crucial Sjögren’s syndrome treatments of all major market players.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers


Table of Contents

1. Sjögren’s syndrome Market – Methodology and Scope

1.1. Research Methodology

1.2. Scope of the Report

2. Sjögren’s syndrome Market – Trends

2.1. Key Trends & Developments

3. Sjögren’s syndrome Market – Industry Analysis

3.1. Market Drivers

3.1.1. The growing patient population of diseases that can cause SS

3.1.2. Increasing awareness about the disease and hence the demand for advanced treatment

3.1.3. The launch of Bristol-Myers Squibb’s Orencia

3.2. Market Restraints

3.2.1. Lack of cure for Sjögren’s syndrome

3.3. Threats and Opportunities

3.4. Porter’s 5 Forces

4. Global Sjögren’s syndrome Market – Market Analysis

4.1. Sjögren’s syndrome Market – By Drug Class

4.1.1. Cholinergic Agonists Salagen (Pilocarpine Hydrochloride) Evoxac (Cevimeline Hydrochloride)

4.1.2. Off-Label Drugs Tear and Saliva Substitutes Cyclosporine Ophthalmic Emulsion – Restasis, Ikervis, Papilock Mini Topical Ophthalmic Corticosteroids – Prednisolone, Fluorometholone, Loteprednol Antimalarial Agents – Hydroxychloroquine Other Systemic Immunosuppressive Therapies – Methotrexate, Azathioprine, Cyclophosphamide Systemic Corticosteroids – Prednisolone, Methylprednisolone Biologic Agents – Rituxan (Rituximab)

4.2. Sjögren’s syndrome Market – By Type

4.2.1. Primary Sjogren’s Syndrome

4.2.2. Secondary Sjogren’s Syndrome

4.3. Sjögren’s syndrome Market – By Distribution Channel

4.3.1 Hospitals

4.3.2 Retail Pharmacy

4.3.3 Online Pharmacy

5. Global Sjögren’s syndrome Market – Geographical Analysis

5.1. North America

5.1.1. The USA

5.1.2. Canada

5.1.3. Mexico

5.2. Europe

5.2.1. Germany

5.2.2. France

5.2.3. The UK

5.2.4. Italy

5.2.5. Spain

5.2.6. Rest of Europe

5.3. Asia Pacific

5.3.1. China

5.3.2. Japan

5.3.3. India

5.3.4. Australia

5.3.5. Rest of Asia Pacific

5.4. South America

5.4.1. Brazil

5.4.2. Argentina

5.4.3. Rest of South America

5.5. Rest of the World

6. Global Sjögren’s syndrome Market – Competitive Landscape

6.1. Market Share Analysis

6.2. Mergers and Acquisitions Analysis

6.3. New Product Launches

7. Global Sjögren’s syndrome Market – Company Profiles

7.1. Novartis AG

7.2. Allergan Inc.

7.3. Otsuka Pharmaceutical Co., Ltd.

7.4. Santen Pharmaceutical Co., Ltd.

7.5. Nicox S.A.

7.6. Argentis Pharmaceuticals, LLC.

7.7. Auven Therapeutics

7.8. Bridge Pharma Inc.

7.9. Cellzome GmbH.

8. Global Sjögren’s syndrome Market – Appendix

8.1. Sources

8.2. List of Tables

8.3. Expert Panel Validation

8.4. Disclaimer

8.5. Contact Us

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Get your FREE SAMPLE PROPOSAL with a single click!